Yoshie O, Aso H, Nanjo M, Tamura K, Ebina T, Ishida N
Jpn J Cancer Res. 1986 Apr;77(4):413-8.
Recombinant human interferon alpha A/D (IFN alpha A/D) is known to be as active on murine cells as on human cells. We studied the antitumor effect of pure IFN alpha A/D on Meth-A sarcoma subcutaneously transplanted into female syngeneic BALB/c mice. When administered systematically (intraperitoneally), IFN alpha A/D was only marginally (but significantly, P less than 0.05) effective in inhibiting tumor growth. With intralesional injection, however, IFN alpha A/D strongly suppressed the growth of Meth-A sarcoma, even leading to complete tumor regression and to subsequent immunity to Meth-A sarcoma cells in the host mice when the treatment was started early after tumor transplantation and with a high IFN alpha A/D dose. We also found that treatment of mice with IFN alpha A/D increased the level of serum alpha 1-acid glycoprotein, one of the acute-phase proteins.
重组人干扰素αA/D(IFNαA/D)已知对鼠细胞和人细胞具有相同的活性。我们研究了纯IFNαA/D对皮下移植到同基因雌性BALB/c小鼠体内的Meth-A肉瘤的抗肿瘤作用。当系统性给药(腹腔内注射)时,IFNαA/D在抑制肿瘤生长方面仅有微弱(但显著,P<0.05)的效果。然而,通过瘤内注射,IFNαA/D强烈抑制了Meth-A肉瘤的生长,当在肿瘤移植后早期且使用高剂量的IFNαA/D进行治疗时,甚至导致肿瘤完全消退,并使宿主小鼠随后对Meth-A肉瘤细胞产生免疫。我们还发现,用IFNαA/D治疗小鼠会增加血清α1-酸性糖蛋白(一种急性期蛋白)的水平。